Clinical trials: Chronic Obstructive Pulmonary
COPD (Chronic Obstructive Pulmonary Disease)
Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients
This multicenter, retrospective-prospective, cohort study aims to evaluate the effectiveness and safety of Extra-fine Beclometasone Diproprionate/Formoterol Fumarate/Glycopyrronium Bromide (EF-BDP/FF/GB) therapy in adults with…
- Trial name
- RETRIBUTE (NCT07406048)
- Testing
- BDP/FF/GB (100ug/6ug/12.5ug)
- Where
- Brazil
- Volunteers
- 396 people
- Sponsor
- Chiesi Farmaceutica Ltda.
Cystic Fibrosis, Chronic Obstructive Pulmonary Disease
A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects
This is a randomized, double-blind, cross-over, vehicle-controlled study to determine whether GS-5737 in 2.8% saline accelerates mucociliary clearance (MCC) in healthy subjects, compared to vehicle of 2.8% saline alone.
- Trial name
- NCT01793649
- Testing
- GS-5737
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1b Study of PUR1800 in Patients With COPD
This is a randomised, placebo-controlled, double-blind 3-way crossover study in which PUR1800, or placebo is dosed daily for 14 consecutive days in adult subjects with stable COPD over three discrete TPs.
- Trial name
- NCT04759807
- Testing
- PUR1800 250 ug, PUR1800 500 ug
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Pulmatrix Inc.
Study is Being Conducted in Healthy Volunteers
A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers
This study will be conducted to establish the relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with and without a spacer device.
- Trial name
- NCT02934607
- Testing
- Symbicort pMDI with spacer device, Symbicort pMDI without spacer device
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)
To investigate possible problems or questions in safety and effectiveness of salmeterol and fluticasone in patients with chronic obstructive pulmonary disease (bronchitis chronic / emphysema).
- Trial name
- NCT01332409
- Testing
- Salmeterol and Fluticasone
- Where
- Japan
- Volunteers
- 2,000 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease
The objective of this study was to compare the bronchodilator efficacy and safety of ipratropium bromide HFA-134a inhalation aerosol and marketed, Atrovent® CFC Inhalation Aerosol in COPD patients
- Trial name
- NCT02260011
- Testing
- Ipratropium bromide HFA-134a inhalation aerosol, Atrovent® CFC inhalation aerosol
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
COPD (Chronic Obstructive Pulmonary Disease)
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD.
- Trial name
- STRIDE (NCT07612878)
- Testing
- Cohort 1: Dupilumab, Cohort 2: usual care only
- Where
- 7 sites in United States
- Volunteers
- 350 people
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive
Evaluating the Clinical Effectiveness of a Patient-specific Silicone Stent
The goal of the trial is to establish a method, material, and patient-specific stent design that will last longer, fit better, and cause less trauma to the airway and the patient.
- Trial name
- NCT05050591
- Testing
- Patient-Specific Silicone Airway Stent
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- VisionAir Solutions
Pulmonary Disease, Chronic Obstructive
Ba253BINEB Compared to Ba253MDI (Metered Dose Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to investigate the efficacy and safety of Ba253BINEB during the continuous 4 weeks administration to the patients with COPD using Ba253MDI (Tersigan® aerosol) as the comparator drug.
- Trial name
- NCT02182583
- Testing
- Ba253MDI, Ba253BINEB
- Volunteers
- 163 people
- Sponsor
- Boehringer Ingelheim
COPD, Arrhythmia
Perry Virtual - A Prospective and Observational Rural Health Trial
The principal objective of the study is to determine if patient-empowered, real-time and home- based patient monitoring of vital parameters can lead to: Reduction in admission rates and improved clinical management of chronically…
- Conditions
- COPD, Arrhythmia, Murmur, Heart, Chronic Disease
- Trial name
- NCT04483154
- Testing
- Coala Heart Monitor
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Coala Life, Inc
Pulmonary Disease, Chronic Obstructive
A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to assess the safety and efficacy of a single dosage strength of GW685698/GW642444 in subjects with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00731822
- Testing
- GW685698/GW642444
- Where
- 9 sites in Norway, Sweden
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events
Background: Recent observational studies have reported possible arrhythmogenic effects with long-acting beta-agonists (LABA), while the long-acting anticholinergic tiotropium has been associated with cardiovascular and…
- Trial name
- NCT02096731
- Where
- Canada
- Volunteers
- 115,397 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)
Primary Objective To demonstrate that CHF 1535 pMDI is non-inferior to Symbicort® Turbohaler® in terms of pulmonary function (change from baseline in pre-dose morning FEV1 at Week 24) in patients with COPD.
- Trial name
- FORSYYN (NCT03888131)
- Where
- 53 sites in China
- Volunteers
- 750 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers
This study is an open label, randomized, three-way crossover study to assess the effect of particle size on the PK and safety of single inhaled doses of AZD7594 in healthy subjects (males aged 18 to 55 years [inclusive]).
- Trial name
- NCT02928354
- Testing
- Treatment A - AZD7594, Treatment B - AZD7594, Treatment C - AZD7594
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.
This non-Interventional, descriptive, cross-sectional cohort and multicentre study will be conducted with COPD patients attended at Spanish Primary Care offices.
- Trial name
- NCT03611777
- Testing
- Inhaled corticosteroid
- Where
- 169 sites in Spain
- Volunteers
- 901 people
- Sponsor
- Boehringer Ingelheim
Asthma
Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).
The purpose of this study is to evaluate the level of satisfaction experienced by asthma or chronic obstructive pulmonary disease (COPD) patients when using the Fluticasone/Salmeterol HFA Metered Dose Inhaler (MDI) with counter…
- Trial name
- NCT00404261
- Testing
- Fluticasone/Salmeterol HFA
- Where
- 4 sites in Australia
- Volunteers
- 132 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]
The primary objective of this pragmatic study is to compare the time to first moderate or severe COPD exacerbation in patients, not controlled on their current therapy, randomized to Stiolto Respimat versus triple therapy over 12…
- Trial name
- NCT03265145
- Testing
- Stiolto Respimat, ICS (Inhaled Corticosteroid) (Triple therapy), LABA (Long-Acting Beta Agonist) (Triple therapy)
- Where
- 90 sites in United States
- Volunteers
- 714 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva
To evaluate acute effect of single dose of ipratropium (Atrovent) or fenoterol (Berotec) in comparison to placebo when given to COPD patients on pharmacodynamic steady state of tiotropium (Spiriva)
- Trial name
- NCT00274066
- Testing
- Tiotropium + ipratropium, Tiotropium + fenoterol
- Where
- 5 sites in Netherlands
- Volunteers
- 65 people
- Sponsor
- Boehringer Ingelheim
Respiratory Disorders
Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia Pacific
Since the infectious aetiology of AECOPD has been suggested to vary according to geographical region, the primary purpose of this study (which will be conducted in several countries in Asia Pacific) is to evaluate the occurrence…
- Trial name
- NCT03151395
- Testing
- Sputum and blood sampling
- Where
- 19 sites in Hong Kong, Philippines and 2 more
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study
The primary purpose of this study is to assess the effectiveness of TRELEGY ELLIPTA single inhaler triple therapy (SITT) (fluticasone furoate/umeclidinium bromide/vilanterol [FF/UMEC/VI]) relative to non-ELLIPTA multiple inhaler…
- Trial name
- LEGEND (NCT03949842)
- Testing
- Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists, Fluticasone furoate/umeclidinium/vilanterol
- Where
- 3 sites in United States
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.